Skip to Content

Join the 'Zyclara' group to help and get support from people like you.

Zyclara News

Retail Prices of Dermatology Drugs Skyrocket

Posted 25 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 25, 2015 – Patients using prescription creams, gels, sprays and pills for skin conditions may shell out substantially more at the pharmacy than they did just six years ago, a new study suggests. Between 2009 and 2015, retail prices of brand-name dermatologic drugs rose 401 percent, on average, study authors reported Nov. 25 in JAMA Dermatology. Even generics have succumbed to price inflation, up 279 percent between 2011 and 2014, based on the drugs surveyed. Price increases for skin treatments far outpaced the general inflation rate of 11 percent during the six-year study period, the researchers said. "Cancer drugs were the worst in terms of the numbers" – up 1,240 percent or nearly $11,000 over the six-year study period – primarily because of two medicines, said Dr. Steven Rosenberg, voluntary professor of dermatology at the University of Miami Miller School of ... Read more

Related support groups: Monistat, RID, Monistat 3, Eczema, Voltaren Gel, Monistat 7, Dermatitis, Clobetasol, Contact Dermatitis, Bactroban, Mupirocin, Therapeutic, Maintain, Hypercare, Drysol, Sulfur, Retin-A, Efudex, Fluocinonide, Epiduo

Rise in Vulvar Precancers Leads to New Guidelines

Posted 20 Oct 2011 by Drugs.com

THURSDAY, Oct. 20 – The number of American women with precancerous cells of the vulva increased more than fourfold between 1973 and 2000, and the increase has led to the release Thursday of new treatment guidelines by two major medical groups. Cancer of the vulva – the outside of the genital area – is usually caused by infection with human papillomavirus (HPV), which also causes cervical cancer. The precancerous condition – known as vulvar intraepithelial neoplasia (VIN) – should be treated with surgery, laser removal or medical therapy, according to the new guidelines from the American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology. VIN is divided into two main types. Usual-type VIN is often associated with cancer-causing strains of HPV and risk factors such as smoking and a weakened immune system. Differentiated VIN is ... Read more

Related support groups: Human Papilloma Virus, Aldara, Imiquimod, Zyclara, Gardasil, Human Papillomavirus Vaccine, Cervarix

FDA Approves Zyclara (imiquimod) Cream, 2.5% for the Treatment of Actinic Keratoses

Posted 29 Jul 2011 by Drugs.com

BRISTOL, Tenn.--(BUSINESS WIRE)--Jul 18, 2011 - Graceway Pharmaceuticals, LLC (Graceway) announced today that the Food and Drug Administration (FDA) has approved Zyclara Cream, 2.5% for the treatment of actinic keratoses, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses (AK). The new formulation may be used on the full face or balding scalp in a convenient 6-week dosing cycle. "The addition of a 2.5% formulation of Zyclara Cream will provide healthcare practitioners greater flexibility when prescribing imiquimod therapy for patients with actinic keratoses," said Dr. Darrell S. Rigel, a clinical professor of dermatology at New York University Medical Center and a former president of the American Academy of Dermatology. "The lower concentration offers greater tolerability while maintaining the efficacy that has long ... Read more

Related support groups: Imiquimod, Actinic Keratosis, Zyclara

FDA Approves Zyclara (imiquimod) Cream, 3.75% for the Treatment of External Genital Warts

Posted 27 Mar 2011 by Drugs.com

BRISTOL, Tenn.--(BUSINESS WIRE)--Mar 25, 2011 - Graceway Pharmaceuticals announced today that the Food and Drug Administration (FDA) has approved Zyclara Cream for the treatment of external genital and perianal warts (EGW) in patients 12 years of age and older. Zyclara Cream's clinical studies demonstrated that using its once-daily treatment regimen, for up to eight weeks, safely and effectively clears genital warts. In addition, data showed that of those patients who achieved complete clearance, only a small number experienced a recurrence of their wart(s) 12 weeks after treatment. Most approved topical prescription treatments currently available to treat EGW are associated with lengthy treatment regimens, which may impact patient compliance. Zyclara Cream was developed to meet the need for a shorter treatment regimen, while maintaining the efficacy (both initial and sustained ... Read more

Related support groups: Imiquimod, Zyclara, Condylomata Acuminata, Genital Warts

Ask a Question

Further Information

Related Condition Support Groups

Keratosis, Condylomata Acuminata

Zyclara Patient Information at Drugs.com